Sat, Sep 20, 2014, 8:55 AM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

IntelliCell BioSciences, Inc. Message Board

toeinmouth 113 posts  |  Last Activity: Mar 20, 2014 6:10 PM Member since: Feb 3, 2012
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Total and complete collapse of pps today?

    by surfntravel Mar 20, 2014 3:23 PM
    toeinmouth toeinmouth Mar 20, 2014 6:07 PM Flag

    you may be kicking yourself very soon and wishing you would've bought a lot more

    Sentiment: Strong Buy

  • Reply to

    Big day for #intellicellbiosciences stock!!!

    by surfntravel Mar 20, 2014 5:57 PM
    toeinmouth toeinmouth Mar 20, 2014 6:03 PM Flag

    I know it hasn't been a good week with SVFC and we all feel the pain However we will go back up to .01 this week or the next.!

    MARK THIS POST

    Sentiment: Strong Buy

  • toeinmouth by toeinmouth Mar 20, 2014 5:58 PM Flag

    BOUNCE OFF OF .005

    Sentiment: Strong Buy

  • Reply to

    It all starts tomorrow!

    by toeinmouth Mar 19, 2014 5:32 PM
    toeinmouth toeinmouth Mar 20, 2014 5:53 PM Flag

    I love you too!!

    Sentiment: Strong Buy

  • toeinmouth by toeinmouth Mar 19, 2014 5:32 PM Flag

    the pps should start to move up tomorrow. The shorts have been covering and changing their short positions to long positions over the last few days. Tomorrow we should see a move up to .0065/.007 and Friday we continue the move up through .008. but that is just the start! The first part of next is looking to be very promising! I see a move through the 200dma (.0145) and then some before a small pull back to the 200dma witch will become support. We should consolidate for a week or two before the next buy signal, the GOLDEN CROSS!!!

    This is just my opinion

    good luck and GO SVFC

    Sentiment: Strong Buy

  • toeinmouth by toeinmouth Mar 12, 2014 4:04 PM Flag

    #$%$!????????????????????????????????????

    Sentiment: Strong Buy

  • Reply to

    Can someone explain the news please?

    by lemmakinen Mar 10, 2014 4:59 PM
    toeinmouth toeinmouth Mar 10, 2014 6:30 PM Flag

    This is old news. We have known about the share increase for many weeks. The reason for the pop in the pps is that we are expecting news "very soon" and we expect that the shares will be used for a partnership/ non dilutive financing or JV

    Sentiment: Strong Buy

  • toeinmouth by toeinmouth Mar 4, 2014 5:09 PM Flag

    It looks like everybody that wants in is in, and everybody that's wants out is out. So now we wait for what is next.

    Sentiment: Strong Buy

  • Sorry! ihub posted that and some smart people on the SVFC board found it to be a mistake by ihub

    That being said, We are golden with SVFC !!!

    Sentiment: Strong Buy

  • Reply to

    The Allstate Corporation

    by toeinmouth Feb 17, 2014 7:30 PM
    toeinmouth toeinmouth Feb 18, 2014 8:45 AM Flag

    sorry, I was late to the game. no harm ment

    Sentiment: Strong Buy

  • toeinmouth by toeinmouth Feb 17, 2014 7:30 PM Flag

    Date: February 13, 2014
    SCHEDULE 13G

    Allstate Insurance Company, an indirect wholly-owned subsidiary of The Allstate Corporation, is the owner of 1,285,474 shares or 8.4% of the Common Stock outstanding of the Company. (SVFC)

    Sentiment: Strong Buy

  • Statement of Ownership (sc 13g)

    Date : 02/14/2014 @ 12:17PM
    Source : Edgar (US Regulatory)
    Stock : Intellicell Biosciences, Inc. (QB) (SVFC)
    Quote : 0.0054 0.0001 (1.89%) @ 7:21PM



    Statement of Ownership (sc 13g)




    Print


    Alert



    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. n/a )*



    ISHARES MSCI EAFE MINIMUM VOLATILITY ETF

    (Name of Issuer)

    COMMON STOCK


    (Title of Class of Securities)

    46429B689


    (CUSIP Number)

    12/31/2013


    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    x Rule 13d-1(b)

    o Rule 13d-1(c)

    o Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).



    CUSIP No: 46429B689

    1

    NAMES OF REPORTING PERSONS



    The Allstate Corporation





    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)




    36-3871531







    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)




    (a) o




    (b) o







    3

    SEC USE ONLY












    4

    CITIZENSHIP OR PLACE OF ORGANIZATION




    Delaware






    NUMBER OF
    5

    SOLE VOTING POWER

    SHARES
    0

    BENEFICIALLY
    OWNED BY
    6

    SHARED VOTING POWER

    EACH


    Allstate Insurance Company - 1,285,474

    REPORTING
    PERSON WITH:
    7

    SOLE DISPOSITIVE POWER


    0



    8

    SHARED DISPOSITIVE POWER


    Allstate Insurance Company - 1,285,474





    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON




    1,285,474







    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) o







    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)




    8.4%







    12

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)




    IC


    Item 1.



    (a)

    Name of Issuer






    ISHARES MSCI EAFE MINIMUM VOLATILITY ETF











    (b)

    Address of Issuer’s Principal Executive Offices






    400 Howard Street

    San Francisco, CA 94105


    Item 2.



    (a)

    Name of Person Filing








    The Allstate Corporation















    (b)

    Address of Principal Business Office or, if none, Residence


    2775 Sanders Road






    Northbrook, IL 60062















    (c)

    Citizenship








    Delaware















    (d)

    Title of Class of Securities








    Common Stock















    (e)

    CUSIP Number








    46429B689




    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:



    (a)
    o
    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).













    (b)
    o
    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).











    (c)
    x
    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).













    (d)
    o
    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).













    (e)
    o
    An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);













    (f)
    o
    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);













    (g)
    o
    A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);













    (h)
    o
    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);













    (i)
    o
    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);













    (j)
    o
    A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J).













    (k)
    o
    A group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:


    Item 4. Ownership.

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.



    (a)

    Amount beneficially owned: 1,285,474













    (b)

    Percent of class: 8.4%













    (c)

    Number of shares as to which the person has:















    (i)

    Sole power to vote or to direct the vote: 0















    (ii)

    Shared power to vote or to direct the vote: 1,285,474















    (iii)

    Sole power to dispose or to direct the disposition of: 0















    (iv)

    Shared power to dispose or to direct the disposition of: 1,285,474


    Item 5. Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following .

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

    Not Applicable

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

    Allstate Insurance Company, an indirect wholly-owned subsidiary of The Allstate Corporation, is the owner of 1,285,474 shares or 8.4% of the Common Stock outstanding of the Company.



    Item 8. Identification and Classification of Members of the Group

    Not Applicable

    Item 9. Notice of Dissolution of Group

    Not Applicable

    Item 10. Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: February 13, 2014

    By:

    /s/ Paul Schutt






    Name: Paul Schutt






    Title: Vice President Investment Finance


    Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)

    Sentiment: Strong Buy

  • Reply to

    Consolidation is good

    by toeinmouth Feb 7, 2014 8:47 AM
    toeinmouth toeinmouth Feb 13, 2014 4:35 PM Flag

    It looks like this consolidation is just about over. We need to break and hold .006 and then we will move up fast until .009 and don't forget with news we will see multi pennies within hours!

    Sentiment: Strong Buy

  • toeinmouth toeinmouth Feb 7, 2014 5:19 PM Flag

    It will take off and there are very nice buying opportunities! :-)

    Yep I picked up some more today!! :) And will be loading up big time on Wednesday

    Sentiment: Strong Buy

  • toeinmouth by toeinmouth Feb 7, 2014 8:47 AM Flag

    SVFC is consolidating right now and the longer the consolidation the larger the move! SVFC will make its move soon! be patient!

    Sentiment: Strong Buy

  • Reply to

    "SVFC" is the real deal....

    by rain0033 Jan 17, 2014 7:51 PM
    toeinmouth toeinmouth Feb 6, 2014 10:12 PM Flag

    I also have several million and will be adding more when funds clear (Wednesday) Don't let this consolidation scare you this is very healthy and we will move up from here after Wednesday :)

    Sentiment: Strong Buy

  • Reply to

    SVFC only stemcell to qualify FDA

    by toeinmouth Feb 4, 2014 8:22 PM
    toeinmouth toeinmouth Feb 4, 2014 8:26 PM Flag

    Moreover, it is because no enzymes are necessary in Intellicell’s process that they are the only public commercial stem cell company in the United States to meet FDA Rule 361 exemption. Under the FDA’s Rule 361, IntelliCells is currently authorized to commercially sell its SVF stem cells in the U.S. The PR announcing the most recent FDA inspection of the company’s flagship lab can be found here. The copy of the FDA report can be obtained by following this link. Note that most of the observations cited in the report are minor and can be corrected easily. When the FDA spends four days in ANY lab, they WILL find something – it’s just the way the game goes.

    Additionaly, the company previously announced that “it has received the results of its independent laboratory audit by Biologic Consultant Group and the audit showed that the new lab at 460 Park Avenue, New York, NY was cGTP compliant.”

    Futhermore, as announced here, Intellicell “has been notified according to the FDA validation registration number 3009842420, that its new facility located at 460 Park Avenue, New York, NY 10022 is now registered to recover, process, package, store, and label human cells and tissue products (HCT/P's) such as the IntelliCell autologous stromal vascular fraction cellular product.”

    Intellicell Biosciences wins key listing from the FDA

    Finally, according to this news release, Intellicell “has been granted a Research Tissue Banking License by the New York State Department of Health.” Which will now allow the company to engage in “the development of autologous and allogenic stromal vascular fraction tissue for researchers around the world.”

    Sentiment: Strong Buy

  • US Federal Appeals Court Sides with FDA: Propagated Stem Cells Are a Drug

    Posted on February 4, 2014


    USA v Regenerative SciencesA long-standing debate in the commercial stem cell arena has focused on whether stem cells grown in a lab prior to clinical use as a transplantation product are biological drugs subject to full FDA vetting. The alternative view has been that such stem cell products are not drugs, but rather are simple human cellular and tissue products.

    That debate, at least operatively, would seem to be over with a ruling today by the federal D.C. Court of Appeals supporting the FDA position that stem cells grown in a lab are in fact drugs. The decision came on an appeal of a lower district court ruling in USA v. Regenerative Sciences case, which had also supported the FDA position.

    Judge Griffith, writing for the majority of the Appeals Court:

    GRIFFITH, Circuit Judge: In this civil enforcement action, we must decide whether the appellants—three individuals and a related corporate entity—violated federal laws regulating the manufacture and labeling of drugs and biological products by producing, as part of their medical practice, a substance consisting of a mixture of a patient’s stem cells and the antibiotic doxycycline. Because we conclude that they did, we affirm the district court’s judgment and the permanent injunction it entered against appellants.

    The Court also described the Regenerative Sciences procedure:

    The Procedure begins with the extraction of a sample of a patient’s bone marrow or synovial fluid. From that sample, Regenerative Sciences isolates mesenchymal stem cells (MSCs), which are capable of differentiating into bone and cartilage cells. The MSCs are then placed in a solution to culture them—that is, to cause them to divide and proliferate.

    Other substances are sometimes added to the solution that affect the MSCs’ differentiation. The culturing process determines the growth and biological characteristics of the resulting cell population. When the MSCs are sufficiently numerous for re-injection, they are combined with doxycycline, an antibiotic obtained in interstate commerce and used to prevent bacterial contamination of the MSCs. The resulting mixture (the Mixture) is injected into the patient from whom the stem cell sample was initially taken, at the site of the damaged tissue.

    In its ruling the Court emphasized it was not simply deferring to the FDA opinion on the matter, but made the ruling based on evidence.

    I asked Dr. Chris Centeno, the leader of Regenerative Sciences, a few questions about his reaction to today’s ruling.

    What’s your take on the ruling? Centeno: The DC Circuit agreed with the FDA’s position. Not much more to it.

    Was it just a “yes/no” kind of situation or are there subtleties to what the court said? Centeno: They basically said that a physician producing what the FDA considers a drug (in our case culturing autologous MSCs) is subject to FDA federal drug rules and isn’t practicing medicine.

    What’s next for Regenerative Sciences? Appeal to Supreme Court? What would that entail? Centeno: We will abide by their ruling as we have done since August of 2010. At that time we got our first written indication of a formal FDA position and we complied by no longer culturing cells at our Colorado medical practice. We will make every effort to continue to comply and we will not pursue appeal to the Supreme Court.

    The ruling along with Dr. Centeno’s indication of there most likely being no further appeal would seem to cement as the law of the land that propagated stem cells, even when used in an autologous context, are drugs, particularly when mixed with other substances or in other ways more than minimally manipulated. This development confirms my #8 prediction for the stem cell field for 2014 and I support this ruling

    Sentiment: Strong Buy

  • Reply to

    DD compilation

    by toeinmouth Feb 2, 2014 3:19 PM
    toeinmouth toeinmouth Feb 3, 2014 9:21 PM Flag

    bump

    Sentiment: Strong Buy

SVFC
0.0014+0.0001(+7.69%)Sep 19 3:59 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Sears Holdings Corporation
NasdaqGSFri, Sep 19, 2014 4:00 PM EDT
Dresser-Rand Group Inc.
NYSEFri, Sep 19, 2014 4:04 PM EDT